TX-FLUENCE
21.9.2022 15:11:14 CEST | Business Wire | Press release
Fluence, a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, has been selected by Wageningen University & Research (WUR) as the LED technology partner for its new Netherlands Plant Eco-phenotyping Centre (NPEC). In NPEC’s state-of-the-art phenotyping greenhouse, VYPR DUO 3x2 fixtures are used to support research on genotype-phenotype associations.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220921005421/en/
In NPEC’s state-of-the-art phenotyping greenhouse, VYPR DUO 3x2 fixtures are used to support research on genotype-phenotype associations. (Photo: Business Wire)
The official opening of NPEC will take place preceding the weeklong International Plant Phenotyping Symposium 2022 (IPPS 2022), held from Sept. 26 to Sept. 30 in Wageningen, Netherlands. Fluence, a Gold Sponsor of IPPS 2022, will attend the conference and opening of NPEC in Wageningen.
NPEC consists of six modules across two university campuses, each offering dedicated phenotyping platforms with its own measurement systems. A specialized greenhouse at the WUR campus houses five climate-controlled compartments outfitted with Fluence’s VYPR DUO 3x2 fixtures. The compartments’ 3D and hyperspectral imaging, conveyor systems and various sensors produce high-precision measurements—including plant size, color and leaf positioning—that can be examined to understand the genetic response of plants to varied conditions and treatments, such as heat, drought or increased soil salinification.
“Using highly customizable technologies that generate high-quality plant performance data on how environmental parameters affect the plant phenotype was a key requirement when selecting our equipment partners,” said Rick van de Zedde, senior scientist and project manager for NPEC. “Having worked with Fluence for the lighting in our Serre Red high-tech quarantine greenhouse, we knew PhysioSpec™️ BROAD R4 white spectrum fixtures could help establish a near-ideal research environment in the NPEC greenhouse.”
In addition to Fluence’s VYPR top lights, which feature PhysioSpec™️ BROAD R4 white spectrum, NPEC researchers will use the Maxi-MARVIN imaging cabinet to assist in research, a high-throughput 3D modeling system developed by WUR that can reconstruct a plant’s architecture within milliseconds. Other high-tech research tools at WUR include a dark and light adaptation chamber and imaging systems capability to analyze the photosynthetic efficiency of plants.
“Establishing research on genotype-phenotype associations, specifically how ecological and environmental variables impact the plant phenotype, is essential for the development of novel, climate-proof crops,” explained van de Zedde. “Automated phenotyping will also allow for a dramatic increase in the speed of plant breeding and time to market for novel crop varieties.”
“We are honored to partner with WUR to advance the future of high-quality food production and sustainability in cultivation,” said Theo Tekstra, Fluence’s technical director for Europe, the Middle East and Africa and team lead for the WUR project. “Our PhysioSpec™️ BROAD R4 white spectrum came closest to what the WUR scientific team defined as an ideal spectrum to do year-round research on a wide range of plant species.”
Fluence's continuing partnership with WUR also includes LED fixtures in a specialized greenhouse for insect research and phenotyping climate rooms at Wageningen. Read more about Fluence’s collaborations with WUR here.
For more information on Fluence, visit www.fluence.science.
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220921005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 15:00:00 CEST | Press release
Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized autho
BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release
Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical
OpenGate Capital to Acquire Maersk Training, the Global Safety Training and Gas-Safety Services Business of Maersk10.8.2026 08:00:00 CEST | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has signed a definitive agreement to acquire Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services that operates through two complementary business segments. The first segment, Maersk H2S Safety Services, is a specialist provider of outsourced hydrogen sulphide and Health, Safety and Environment safety services, which include onsite supervision, monitoring and safety equipment maintenance for customers in high-risk operating environments. The second segment, Training Business, is a global provider of safety training, competency development and simulation, delivered through instructor led, digital and virtual
Ant International’s Bettr Partners with Muslim Pro to Introduce Umrah Financing Service in Malaysia10.8.2026 05:49:00 CEST | Press release
Bettr, a leading provider of inclusive and embedded finance and fintech solutions under Ant International, today announced its partnership with Muslim Pro, a popular Islamic lifestyle app serving over 190 million downloads worldwide, to launch an Umrah financing solution in Malaysia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260809780047/en/ Ant International's Bettr and Muslim Pro launch an Umrah financing solution in Malaysia to help families better manage their cash flow and spread pilgrimage costs responsibly. The solution is designed for eligible Muslims who have the means to undertake the pilgrimage but prefer to spread its cost over time. This flexibility enables individuals and families to manage their cash flow responsibly, maintain regular savings and preserve sufficient liquidity for emergencies and other financial obligations. The launch marks a significant milestone in Bettr’s Islamic finance initiative and
ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings7.8.2026 19:48:00 CEST | Press release
An ICC Arbitral Tribunal has awarded AOP Orphan Pharmaceuticals GmbH (“AOP Health”) a total of about EUR 112 Mio in a quantum award issued in the ongoing arbitration proceedings with PharmaEssentia Corp. (“PharmaEssentia”) concerning BESREMi® (ropeginterferon alfa-2b). The award quantifies AOP Health’s damage claims for PharmaEssentia’s intentional breaches at ca. EUR 82 Mio. It also awards AOP Health ca. EUR 31 Mio plus interest as reimbursement for AOP Health overpayments made to PharmaEssentia as a result of excessive pricing in the years 2019-2022. The Tribunal thereby confirmed that PharmaEssentia has been overcharging AOP Health by up to 900% over these years. The Tribunal affirmed AOP Health's valid set-off of the profit-sharing payments amount owed to PharmaEssentia of approximately EUR 17 Mio against AOP Health's substantially exceeding damages claims. This means that AOP Health shall not make any payment to PharmaEssentia. Interest on AOP Health’s claims will continue to accr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
